GlassScriptPhysician profile
Jey A Maran
NPI 1508835067
$5,225.68
in general payments reported to CMS, 2019-2025
45 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $258 · 2021: $27.54 · 2022: $133 · 2023: $634 · 2024: $2,412 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,862 · Long Term Medical Supply Or Device Loan: $1,847 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,861.56 |
| Long Term Medical Supply Or Device Loan | $1,846.67 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,221.76 | 2023-2025 | |
| Genentech USA, INC. | $259.49 | 2020-2025 | Polivy, Lunsumio, Tecentriq |
| Janssen Biotech, INC. | $249.06 | 2023-2025 | Darzalex, Erleada, Carvykti |
| Pacira Pharmaceuticals Incorporated | $231.97 | 2020 | |
| Bard Peripheral Vascular, INC. | $171.23 | 2022-2025 | Trek |
| Pfizer INC. | $138.81 | 2023-2025 | |
| Bioprotect Medical, INC. | $137.08 | 2024-2025 | Bioprotect Balloon Implant System |
| Exelixis INC. | $118.62 | 2024 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $118.55 | 2024-2025 | Imfinzi, Calquence, Enhertu |
| Abbvie INC. | $113.35 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $112.88 | 2023-2025 | Keytruda |
| Gilead Sciences, INC. | $92.21 | 2021-2025 | Trodelvy |
| Incyte Corporation | $84.53 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Astellas Pharma US INC | $80.55 | 2023-2024 | Padcev |
| Celgene Corporation | $79.10 | 2024-2025 | Opdivo, Opdualag, Pomalyst |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $73.79 | 2024 | Clonoseq |
| Takeda Pharmaceuticals U.S.A., INC. | $68.61 | 2023-2024 | Iclusig, Alunbrig, Ninlaro |
| Genzyme Corporation | $65.17 | 2023-2024 | |
| Genmab U.S., INC. | $62.22 | 2024-2025 | Epkinly |
| Lilly USA, LLC | $61.91 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Tempus Ai, INC | $57.83 | 2024 | Xt Cdx |
| Janssen Pharmaceuticals, INC | $49.73 | 2023-2024 | Xarelto |
| Beone Medicines USA, INC. | $48.52 | 2025 | Tevimbra, Brukinsa |
| Beigene USA, INC. | $40.02 | 2024-2025 | Brukinsa, Tevimbra |
| Stemline Therapeutics INC. | $33.52 | 2023 | Orserdu |
| Alexion Pharmaceuticals, INC. | $33.37 | 2023-2024 | Ultomiris |
| Mirati Therapeutics, INC. | $32.32 | 2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $29.85 | 2023 | Libtayo |
| Amgen INC. | $26.16 | 2023 | Kyprolis |
| Myriad Genetic Laboratories, INC. | $24.96 | 2024 | Myrisk |
| Springworks Therapeutics, INC. | $24.82 | 2024 | Ogsiveo |
| Emd Serono, INC. | $24.73 | 2024 | |
| Daiichi Sankyo INC. | $24.65 | 2024 | Enhertu |
| Coherus Oncology, INC. | $24.29 | 2023 | |
| Glaxosmithkline, LLC. | $23.93 | 2024 | Ojjaara |
| Servier Pharmaceuticals LLC | $23.46 | 2024 | |
| Geron Corporation | $21.19 | 2025 | Rytelo |
| Eisai INC. | $20.37 | 2024 | |
| Array Biopharma INC | $20.30 | 2024 | Mektovi, Tukysa, Braftovi |
| Puma Biotechnology, INC. | $20.22 | 2024 | |
| Novocure INC. | $18.61 | 2025 | Optune Lua (Novottf-200t) |
| Aveo Pharmaceuticals, INC. | $18.52 | 2024 | |
| Alnylam Pharmaceuticals INC. | $16.87 | 2024 | Givlaari |
| Acrotech Biopharma INC. | $15.09 | 2023 | Beleodaq |
| Focal Therapeutics, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jey Maran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.